Compare FTEL & ADTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FTEL | ADTX |
|---|---|---|
| Founded | 2007 | 2017 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7M | 2.0M |
| IPO Year | 2023 | 2020 |
| Metric | FTEL | ADTX |
|---|---|---|
| Price | $0.43 | $0.85 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 2.4M | ★ 2.8M |
| Earning Date | 11-17-2025 | 11-18-2025 |
| Dividend Yield | ★ 49.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,200,138.00 | $5,945.00 |
| Revenue This Year | N/A | $15,768.94 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.42 | N/A |
| 52 Week Low | $0.40 | $0.81 |
| 52 Week High | $187.68 | $6,183.90 |
| Indicator | FTEL | ADTX |
|---|---|---|
| Relative Strength Index (RSI) | 32.85 | 34.87 |
| Support Level | $0.47 | $0.81 |
| Resistance Level | $0.58 | $0.97 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 12.31 | 2.82 |
Fitell Corp conducts its primary operations of selling gym and fitness equipment in Australia through its indirectly held wholly owned subsidiary, serving personal training studios and commercial gyms. Its product coverage includes four proprietary brands: Muscle Motion for strength-training equipment, Rapid Motion with a focus on commercial items, FleetX for cardio equipment, and Harison for cardio, strength, recovery, and conditioning products. The Company operates in one segment, trading gym equipment, and also provides licensing services and gym equipment to overseas gym studios. Majority of its business is conducted in Australia via its e-commerce platform and third-party sites, with maximum revenue earned from retail.
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues.